Floatz logo

rc48-adc

Primary Central Nervous System Lymphoma

Peking Union Medical College Hospitalantibody_drug_conjugatePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Primary Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB
Cyclophosphamide
Juan P. Alderuccio, MD
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Ono Pharmaceutical Co., Ltd.
Phase 4BB

View all 36 →

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →